Surmodics Revenue 2006-2019 | SRDX

Surmodics revenue from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Surmodics Annual Revenue
(Millions of US $)
2018 $81
2017 $73
2016 $71
2015 $62
2014 $57
2013 $56
2012 $52
2011 $53
2010 $54
2009 $122
2008 $97
2007 $73
2006 $70
2005 $62
Surmodics Quarterly Revenue
(Millions of US $)
Q3 2019 $24
Q2 2019 $23
Q1 2018 $22
Q4 2018 $23
Q3 2018 $22
Q2 2018 $19
Q1 2017 $17
Q4 2017 $20
Q3 2017 $18
Q2 2017 $18
Q1 2016 $18
Q4 2016 $18
Q3 2016 $20
Q2 2016 $17
Q1 2015 $17
Q4 2015 $17
Q3 2015 $16
Q2 2015 $14
Q1 2014 $14
Q4 2014 $15
Q3 2014 $15
Q2 2014 $14
Q1 2013 $14
Q4 2013 $14
Q3 2013 $14
Q2 2013 $14
Q1 2012 $14
Q4 2012 $14
Q3 2012 $14
Q2 2012 $12
Q1 2011 $12
Q4 2011 $14
Q3 2011 $13
Q2 2011 $13
Q1 2010 $13
Q4 2010 $16
Q3 2010 $19
Q2 2010 $18
Q1 2009 $17
Q4 2009 $19
Q3 2009 $18
Q2 2009 $21
Q1 2008 $63
Q4 2008 $23
Q3 2008 $24
Q2 2008 $26
Q1 2007 $24
Q4 2007 $21
Q3 2007 $18
Q2 2007 $17
Q1 2006 $17
Q4 2006 $18
Q3 2006 $18
Q2 2006 $18
Q1 2005 $16
Q4 2005 $16
Q3 2005 $17
Q2 2005 $16
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.527B $0.100B
SurModics, Inc. is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. Recent collaborative efforts include the implementation of SurModics' Bravo drug delivery polymer matrix as a key component of the first-to-market drug-eluting coronary stent. SurModics is also active in the ophthalmology market with a sustained drug delivery system that is currently in human trials for treatment of retinal disease. A significant portion of SurModics' revenue is generated by royalties earned from the sale of our customers' commercial products.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $148.090B 27.01
Medtronic (MDT) Ireland $143.599B 20.16
Stryker (SYK) United States $74.738B 25.13
Boston Scientific (BSX) United States $56.464B 26.65
Baxter (BAX) United States $40.084B 24.31
EssilorLuxottica Societe Anonyme (ESLOY) France $32.664B 0.00
Zimmer Biomet Holdings (ZBH) United States $29.619B 18.58
Terumo (TRUMY) Japan $27.722B 0.00
Lonza Group Ag (LZAGY) Switzerland $25.691B 0.00
Coloplast (CLPBY) Denmark $25.121B 0.00
ResMed (RMD) United States $20.684B 38.16
Sunny Optical Technology (SNPTF) China $18.592B 0.00
Smith & Nephew SNATS (SNN) United Kingdom $18.588B 0.00
Bio-Rad Laboratories (BIO) United States $10.550B 50.64
Insulet (PODD) United States $10.476B 498.41
Canopy Growth (CGC) Canada $7.475B 0.00
Hill-Rom Holdings (HRC) United States $6.947B 20.47
Perrigo (PRGO) Ireland $6.812B 12.70
William Demant Holdings (WILYY) Denmark $6.665B 0.00
DiaSorin S.p.A (DSRLF) Italy $6.420B 0.00
Haemonetics (HAE) United States $6.037B 40.79
GN STORE NORD (GNNDY) Denmark $5.276B 0.00
Shandong Weigao Medical Polymer (SHWGF) China $5.155B 0.00
Aurora Cannabis (ACB) Canada $3.920B 0.00
NuVasive (NUVA) United States $3.757B 29.59
ICU Medical (ICUI) United States $3.456B 22.41
GW Pharmaceuticals (GWPH) United Kingdom $3.380B 0.00
Neogen (NEOG) United States $3.369B 56.38
Hutchison China MediTech (HCM) Hong Kong, SAR China $2.987B 0.00
Quidel (QDEL) United States $2.480B 23.54
National Vision Holdings (EYE) United States $2.179B 49.55
Agios Pharmaceuticals (AGIO) United States $1.976B 0.00
Cardiovascular Systems (CSII) United States $1.570B 0.00
InMode (INMD) Israel $1.293B 0.00
Aphria (APHA) $1.275B 0.00
VAREX IMAGING (VREX) United States $1.245B 28.70
AtriCure (ATRC) United States $1.109B 0.00
Phibro Animal Health (PAHC) United States $0.936B 17.53
Eagle Pharmaceuticals (EGRX) United States $0.863B 22.01
Lantheus Holdings (LNTH) United States $0.842B 21.04
NanoString Technologies (NSTG) United States $0.826B 0.00
TG Therapeutics (TGTX) United States $0.775B 0.00
Omeros (OMER) United States $0.669B 0.00
LeMaitre Vascular (LMAT) United States $0.662B 37.49
PetIQ (PETQ) United States $0.655B 16.01
HEXO (HEXO) $0.604B 0.00
Quanterix (QTRX) United States $0.589B 0.00
Cerus (CERS) United States $0.577B 0.00
Organigram Holdings (OGI) Canada $0.572B 0.00
OraSure Technologies (OSUR) United States $0.529B 31.74
Owens & Minor (OMI) United States $0.454B 16.79
MacroGenics (MGNX) United States $0.404B 0.00
Utah Medical Products (UTMD) United States $0.383B 27.79
BioLife Solutions (BLFS) United States $0.341B 104.75
Meridian Bioscience (VIVO) United States $0.337B 11.62
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.328B 0.00
Zynex (ZYXI) United States $0.295B 33.33
Viemed Healthcare (VMD) United States $0.266B 0.00
Bovie Medical (APYX) United States $0.238B 0.00
United Health Products (UEEC) United States $0.185B 0.00
Vapotherm (VAPO) United States $0.183B 0.00
Repro-Med Systems (KRMD) United States $0.172B 0.00
Cytosorbents (CTSO) United States $0.149B 0.00
InfuSystems Holdings (INFU) United States $0.142B 0.00
Liberty Health Sciences (LHSIF) Canada $0.133B 0.00
Female Health (VERU) United States $0.131B 0.00
Fonar (FONR) United States $0.126B 8.87
Rockwell Medical (RMTI) United States $0.118B 0.00
Chimerix (CMRX) United States $0.101B 0.00
United-Guardian (UG) United States $0.085B 21.62
Chembio Diagnostics (CEMI) United States $0.080B 0.00
Nephros (NEPH) United States $0.072B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.053B 0.00
MRI Interventions (MRIC) United States $0.053B 0.00
Surface Oncology (SURF) United States $0.048B 0.00
MTech Acquisition (KERN) United States $0.046B 0.00
ImmuCell (ICCC) United States $0.037B 0.00
Trinity Biotech (TRIB) Ireland $0.023B 0.00
GUARDION HEALTH (GHSI) United States $0.020B 0.00
Senestech (SNES) United States $0.019B 0.00
Myomo (MYO) United States $0.012B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.011B 0.00
Valeritas Holdings (VLRX) United States $0.011B 0.00
Capricor Therapeutics (CAPR) United States $0.008B 0.00
Akers Biosciences Inc (AKER) United States $0.004B 0.00
NeuroMetrix (NURO) United States $0.003B 0.00